ICU Medical (NASDAQ:ICUI) Reaches New 1-Year High – Here’s Why

ICU Medical, Inc. (NASDAQ:ICUI) hit a new 52-week high on Monday . The company traded as high as $162.85 and last traded at $157.1650, with a volume of 213542 shares traded. The stock had previously closed at $157.51.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Zacks Research raised ICU Medical from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 29th. Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Sanford C. Bernstein cut ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Piper Sandler cut their price target on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Finally, KeyCorp lifted their price objective on shares of ICU Medical from $164.00 to $182.00 and gave the stock an “overweight” rating in a research report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $172.00.

ICU Medical Price Performance

The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of 85.82, a P/E/G ratio of 2.20 and a beta of 0.76. The company’s 50-day simple moving average is $142.12 and its 200-day simple moving average is $139.41. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.34 and a quick ratio of 1.17.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million for the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.The firm’s revenue for the quarter was down 12.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Research analysts forecast that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ICU Medical news, Director David C. Greenberg sold 2,424 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the transaction, the director owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Virginia Ruth Sanzone sold 2,447 shares of ICU Medical stock in a transaction on Thursday, May 14th. The stock was sold at an average price of $124.08, for a total value of $303,623.76. Following the sale, the vice president directly owned 19,460 shares of the company’s stock, valued at $2,414,596.80. This represents a 11.17% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of ICU Medical

A number of institutional investors have recently bought and sold shares of ICUI. Norges Bank acquired a new stake in shares of ICU Medical in the fourth quarter valued at approximately $58,083,000. Kirr Marbach & Co. LLC IN increased its stake in ICU Medical by 18.4% during the 1st quarter. Kirr Marbach & Co. LLC IN now owns 44,153 shares of the medical instruments supplier’s stock worth $5,702,000 after acquiring an additional 6,863 shares during the period. F m Investments LLC raised its holdings in ICU Medical by 33.3% in the 4th quarter. F m Investments LLC now owns 46,519 shares of the medical instruments supplier’s stock valued at $6,637,000 after acquiring an additional 11,608 shares in the last quarter. Thrivent Financial for Lutherans raised its holdings in ICU Medical by 1,604.0% in the 4th quarter. Thrivent Financial for Lutherans now owns 303,457 shares of the medical instruments supplier’s stock valued at $43,294,000 after acquiring an additional 285,648 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of ICU Medical by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 2,714,746 shares of the medical instruments supplier’s stock valued at $387,313,000 after acquiring an additional 89,755 shares during the period. Institutional investors own 96.10% of the company’s stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.